A phase ii study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

Tsunekazu Mizushima, Yoshito Ide, Kohei Murata, Ichiro Ohashi, Keigo Yasumasa, Mutsumi Fukunaga, Hiroyoshi Takemoto, Hiroshi Tamagawa, Junichi Hasegawa, Taishi Hata, Ichiro Takemasa, Masataka Ikeda, Hirofumi Yamamoto, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori

研究成果: Contribution to journalArticle査読

7 被引用数 (Scopus)

抄録

Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.

本文言語英語
ページ(範囲)317-322
ページ数6
ジャーナルOncology (Switzerland)
85
6
DOI
出版ステータス出版済み - 12 2013
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「A phase ii study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル